Our own group has studied immunity to HER 2Ineu oncogenic protein as a model "self' tumor antigen. HER-2Ineu protein has several charac teristics that make it an appealing target for vac cine and T-cell-directed therapy. It is overex pressed in human adenocarcinoma and is, therefore, an abundant protein in some cancers. HER-2/neu expression is generally homogeneous throughout the tumor and is present in metastasis" An immune response generated to the antigen could result in complete eradication of both pri mary tumor and metastasis. As a transmembrane molecule, portions of the protein are likely to be availahle to both the class I and class II antigen processing pathways. Potentially, both CD4+ T cells and CD8+ T cells might be invoked to me diate an antitumor immune response. In addition, monoclonal antibodies to the extracellular do main can disrupt signaling fuuction. If antibody could be generated by vaccination, it might have an important role altering growth and inducing differentiation of HER-2/neu-positive tumors.
I. HER·21NEU ONCOGENIC PROTEIN: TUMOR ANTIGEN
have a preexistent immune response to HER-2I neu, proving that vaccines will be able to induce an immune response. Finally, it is has already been shown that several types of passive immu notherapy with antibodies and engineered T cells can be effective, providing strong implication that active immunization can also be effective.
HER-2Ineu is a member of the epidelmal growth factor receptor family and is presumed to function as a growth factor receptor. 3.4 This trans membrane protein consists of a cysteine-rich ex tracellular domain (ECD) that functions in ligand binding and an intracellular cytoplasmic domain (lCD) with kinase activity. Monoclonal antibod ies have been generated to the ECD of HER-21 neu protein that are capable of inducing either stimulatory or inhibitory signals to the receptor. 5, 6 In humans, the HER-2/neu protein is expressed during fetal development. 7 In adults, the protein is weakly detectable in the epithelial cells of many nonnal tissues by immunohistochemical staining. The HER-2Ineu gene is present, in normal cells, as a single copy.' Amplification of the gene and! or overexpression of the associated protein has been identified in many human cancers, Theoreti cally, the overexpression wonld allow for a rela tively selective targeting of malignant cells.
Cancers in which HER-2/neu gene amplifica tion and resultant protein overexpression occur in clude most human adenocarcinomas such as breast, ovary, uterus, prostate, stomach, and lung. [8] [9] [10] [11] [12] The clinical consequences of the oncogenic protein overexpression have been best studied in breast and ovarian cancer. HER-2/neu protein overex pression occurs in 20 to 40% of intraductal carci nomas of the breast and 30% of ovarian cancers. It is associated with a poor prognosis in subcatego ries of both diseases."
In node-positive breast cancer, HER-2/neu protein overexpression has been linked to more aggressive disease and a poorer prognosis. HER 21neu protein overexpression, however, is not al ways related to a bad prognosis. HER -2/neu overexpression is more common in ductal carci noma in situ, a premalignant lesion, than in frank intraductal carcinoma. 14 In addition. an Italian study of a large number of breast cancer patients indicated that HER-2Ineu protein overexpression, in stage 1 disease, in tumors that have inflamma tory infiltrate actually portends a favorable prog nosis.1 5 One hypothesis is that the better outcome in these patients may be related to the generation of a HER-2/neu-specific immune response.
Investigations defining HER-2/neu-specific immunity in patients with cancer, by our labora tory and others, indicate that high levels of immn nity can exist in some patients, but the vast major ity of patients have low or nonexistent HER-21 neu-specific immunity. Therefore, strategies aimed at inducing and boosting the immunity may be very effective in inducing a substantial immune response. Both T cell and antibody immunity exists in some patients. 16-'" The majority ofT-ceil stud ies identified responses in a limited number of patients only, defining T-cell responses after mUltiple restimulations in ,·;tro, These studies are an indication the HER-2/neu-specific immnne response present in most patients with cancer is of low magnitude, One study ofHER-2/neu-specific antibody immunity'" identified a small minority of early-stage patients (lor II) with high titer HER-2Ineu-specific antibodies, The high titer HER-2/neu-specific immunity, found in these few patients with early-stage disease, may indicate the development of an immune response to HER 2Ineu protein expressed by growing tumor limits further growth and metastasis. It has not yet been proven that existent immunity to HER-2Ineu pre dicts for an improved survival, but existent im munity does predict that vaccines will be able to induce and boost immunity to HFJ<-2Ineu, Studies in animal models and in humans have proven that antibody can be effective in eradicating tumor. In one study, a monoclonal antibody spe cific for the ECD of rat neu, a homologue to human HER-2/neu, was infused into mice transgenic for rat neu; animals destined to develop and die of neu mediated breast cancer. Infusion of increasing amounts of 7. 16.4, a neu antibody directed against the ECD'D led to a dose-dependent antitumor re sponse in animals with established tumors. In treated animals, there were fewer satellite tumors and tu mor burden was less than in untreated controls. More important, 50% of neu transgenic mice did not develop breast cancer when treated with 7.16,4, Of note, infusion of antibody resulted in receptor downregulation in vivo. Furthermore, tumors iso lated from treated mice showed evidence of mark edly reduced HER-2/neu tyrosine phosphorylation. Presumably, the downregulation of the HER-2/neu . receptor was, at least partially, responsible for the dramatic effect on survival. These observations suggest that the therapeutic effects we,re mediated through interference with the grov.w factor recep tor activities of HER-2/neu and not through an immunological cascade resulting in the death of tumor cells.
In initial human clinical trials, infusion of another HER-2!neu-specific monoclonal antibody induced tumor regression in some patients with advanced canceL 2 ! Forty-six advanced-stage pa tients, with histories of extensive prior therapy, were treated with weekly infusions of the anti body over an II-week period. The treatment was well tolerated, with minimal toxicity. Objective tumor responses were seen in 5 of 43 assessable patients, including one patient who had a com plete response.
T-cell therapy with cytotoxic T lymphocytes (CTL) expressing recombinant single-chain an tibodies has also been shown to be effective. Chimeric single-chain receptor genes were con structed incorporating both the antigen-binding domain of HER-2/neu-specific antibodies and the zeta chain signal transduction subunit of the TCR/CD3 complex. Expression of the ~himeric single-chain receptor by T cells conferred HER-2/neu protein recognition to T cells without the need for antigen processing of HER-2/neu and without the requirement of MHC restriction. n . 23 The growth of HER-2!neu-transformed cells in nude mice was markedly inhibited by the adop tive transfer of CTL expressing the HER-2/neu antibody/zeta chain construct. 23 Immunization to induce endogenous anti body and T-cell responses might likewise be effective. The mOSt effective way to indnce or boost to "self' oncogenic proteins is unknown. The extent to which immunity to HER-2/neu can be augmented without generating autoimmunity is not known. Finally, the role each arm of the immune response CD4+ T cell, CD8+ T cell, and antibody formation plays in the eradication ofHER-2/neu-positive malignancies has not been defined. HER-2/neu is a transmembrane protein where both antibody and CTL responses may be effective in tumor eradication. The lack of mag nitude of the existing HER -2/neu-specific im mune response, in most cancer patients, indi cates that a lack of T-cell help in augmenting either an antibody or CTL response may be a critical missing link in effective HER-2/neu-spe cific immunity. We began to investigate meth ods to vaccinate to induce an effective T-cell helper response as the first step to the generation of an effective HER -2/neu vaccine.
II. HER·2INEU ONCOGENIC PROTEIN: ISSUES IN VACCINE DESIGN
Once HER-2/neu was defined as a human tumor antigen by identification of existent immu nity in some patients, an immunization strategy to augment immunity in patients with a preexistent immune response or generate immunity in pa tients with no detectable HER-2!neu-specific im mune response needed to be defined. How best to inununize? We used a rat model for assessing the most e.ffective way to vaccinate against the HER-2/neu protein. Previous investigators had shown that rats could not be immunized with rat neu protein in the context of rat ECD in a vaccinia vector. 24 Studies from our laboratory confirmed those findings by vaccinating rats with purified rat neu in a classic immunization regimen 2S Rats were tolerant to rat neu.
We questioned whether tolerance to HER-21 neu could prospectively be circumvented by im munization with peptide-based vaccines. Immu nization to foreign proteins normally elicits im munity to only a subset of potential epitopes, dominanr epitopes, whereas other potentially im munogenic epitopes, subdominant epitopes, are ignored. Immunization to self proteins usually fails to elicit immunity. It has been proposed that the autologous T cells recognize and become tol erant to the dominant epitopes of self proteins, but "ignore" the subdominant epitopes. 26 • 07 Tolerance to the dominant epiropes is elicited by a variety of mechanisms, including elimination in the thymus or periphery or induction of anergy. Immunity to subdominant epitopes can be elicited by immuni zation to proteins truncated to not contain the dominant epitopes or to peptides representing the subdominant epitopes alone.
To test the ability of peptide based vaccines to circumvent tolerance to HER-2!neu protein, we remmed to the rat model. Rats were inunu nized with rat neu peptides designed for eliciting CD4+ T-cell responses. Some animals were im munized with purified rat neu in a similar manner to compare the immunogenicity of intact protein vs. peptides. Antibody and T-cell responses spe cific for both the immunizing peptides and pro tein were generated in the peptide-immunized animals. No antibody or T-cell responses were observed in animals immunized with intact rat neu protein. 25 Tbe use of synthetic peptides as tbe immuniz ing antigens in cancer vaccines offers practical advantages, relatively easy construction and pro duction, chemical stability, and a lack of infec tious or oncogenic potentiap& Peptide, may also allow better manipulation of the immune response through the use of epitope, designed for eliciting particular types of immune responses. Most im portant, peptide vaccines appear to be effective in generating immune responses to self proteins. Unfortunately, peptides are considered weak im munogens. In humans there is a lack of effective and potent adjuvants that allow the augmentation of peptide antigen-specific immune responses. Peptide immunizations have elicited specific im mune responses when injected with powerful adjuvants in animals, but many of these adjuvants are quite toxic for repeated use in humans.
Because of a lack of a "standard" adjuvant for use with peptides in humans, we tested GM-CSF in the preclinical rat model. GM-CSF has been shown, in vitro, to stimulate the growth of antigen presenting cells (APC) such as dendritic cells (DC) and macrophages. GM-CSF has also been shown to increase the immunogenicity of tumors in animal models. 29 Transfecting the cytokine gene into tumor cells, and injecting the transfected cells subcutaneously, results in the production of GM CSF by the tumor cell itself and enhances its immunogenicity. The increased immune response is presumed to be mediated by the role GM-CSF plays in the maturation and function of APC sucb as DC. 3G Further studies using GM-CSF encapsu lated in microspheres mixed with irradiated tu mor cells and injected subcutaneously also dem onstrated increased tumor immunogenicity. 31 These encouraging studies with wbole tumor cell preparations led us to question whether GM-CSF could be useful in augmenting specific antigen responses to peptides by activating and loading APCs such as DC in vivo.
Initial experiments examined whether GM CSF injected into the skin of rats could increase the number of APC, measured as class II MHC expressing cells. in lymph nodes draining the in jection site. Intradermal (i.d.) inoculation of GM CSF every 24 hra for a total of five inoculations resulted in infiltration of class II MHC positive cells that peaked at the fourth inoculation. Subcu taneous (s.q.) inoculation causes that influx to occur more rapidly.'2 Subsequent studies demon strated repeated injections of GM-CSF were not necessary for inducing immunity and that i.d. immunization was more effective than s.q. at elic iting tetanus toxoid-specific immunity. In addi tion, i.d. immunized animals developed a marked tetanus toxoid-speciflc delayed type hypersensi tivity (DTH) response. Extrapolating these stud ies to a rat neu peptide vaccine in rats, rat neu peptides inoculated with GM-CSF could elicit a strong DTH response, whereas peptides alone were nonimmunogenic. Thus, GM-CSF as an adjuvant, increased local antigen presenting cells and en hanced tbe immunogenicity of antigen in both a foreign antigen and tumor antigen system. Animal studies indicated that peptide vac cines utilizing subdominant epitopes plus GM CSF can be an effective way to overcome toler ance. The next issue was the identification of subdominant epitopes in humans. Potential sub dominant HER-2/neu peptides were selected based on motif and extensive in vitro evaluation. HER-2!neu peptides, with the potential for eliciting an immune response, were selected using a com puter protein sequence analysis package that used searching algorithms for identifying motifs ac cording to alpha helical orientation and to charge and polarity patterns and tertiary structure. 33 Al though peptides that bind to class II molecules are now known not to necessarily form alpha helical orientations, each of the searching algorithms had empirically been successful in identifying a sub stantial proportion (50 to 70%) of helper T-cell epitopes in foreign proteins 3435 Analysis resulted in the identification of more than 40 HER -2/neu peptides with the potential to interact with human class II MHC.'6.36 Based on predicted interac tions. 26 peptides, 15 to 18 amino acids in length were constructed. Heparinized blood was obtained from over 60 breast cancer patients and'lympho cytes isolated and tested for proliferative response in standard and modified limiting dilution analysis based on tritiated thymidine ineorporation. Immune response to seven of 26 peptides tested were de tected ill vitro in at least 20% of breast cancer patients evaluated. Thus, extensive imperic testing of proposed helper epitopes ill vitro resulted in the identification of potential subdominant epitopes of HER-2/neu. Si.x of the seven peptides could be reproducibly constructed, three derived from the ECD and three derived from the ICD.
The six peptides have begun to be te,ted in a phase I human vaccine trial. The importance of the CD4+ helper T cells in mediatiug an anti tumor response is increasingly being empha sizedY-39 Our initial clinical studies would at tempt \0 generate a higher magnitude HER-2/neu T helper immune response. We hypothesized that the two domains of the HER-2/neu protein may behave differently immunologically. The ICD may be more immunogenic. As an intercellular pro tein, it is not readily available for immune recog nition and possible tolerance induction. The ECD protein is available as an extracellular protein and in many patients may actually become truncated and circulate in the sera as a soluble protein. 40 For this reason we formulated two vaccines contain ing helper peptides derived from rhe different domains, the ECD and the lCD, for use in hu mans, Three peptides were incorporated in eacb vaccine as a compromise to include a sufficient number of peptides that some response may be elicited in individual patients tested, but not So many peptides included that an epitope that may inhibit the development of a HER-2/neu-specific immune response was present.
HER·21NEU ONCOGENIC PROTEIN: ISSUES IN VACCINE CLINICAL TRIAL DESIGN
The major question to be answered in the first HER-2/neu vaccine study in humans was safety. Do any unexpected and untoward toxicities occur and could immunity to a self tumor antigen be induced without adverse ef fects against cells expressing basal levels of HER-2/neu? A second question: was the vaccine im munogenic'! If the potential side effects related to the immunization were based on the develop ment ofHER-2/neu-specific immunity, then those sid" effects could only be evaluated in relation to the immunity elicited by immunization. The study design was greatly influenced by the established role of vaccines in the prevention of infectious diseases. In general, the major use of vaccines is to prevent disease from occurring (e.g., to protect from infection). Vaccines are not used as front line agents to treat established infection. Simi larly, cancer vaccines may have the greatest thera peutic utility, not in treatment of established disease, but rather in minimal disease states or prevention of recurrence of tumors in high-risk patients. Therefore, our trial is designed to mal'i mize the ability to immunize effectively and the "clinical endpoint" is the generation of HER-2/ neu-specific immunity, not a clinical response in an existing tumor. In fact, it may well be that patients with established ll1mOfs cannot be effec tively immunized by virtue of the immunosup pressive effect of cancer. Key to an effective trial design is the choice of patient popUlation, "dose escalation" of immunizations, and laboratory analysis of the immune response.
An important aspect in tbe design of a phase I cancer vaccine trial targeting a self tumor anti gen is the selection of the patients to be immu nized. Toxicity is possible. Thus, advanced-stage patients are needed for the initial studies. How ever, the determination of safety requires that an immune response be mounted. Far advanced can cer patients are often immune incompetent. There fore, the tumor immunologist must balance pa tient characteristics to fit the riskibenefit ratio yet optimize for the patient with minimal disease. For that reason patients with stage III or IV breast and ovarian cancer are eligible for the study if the following criteria are met: (1) HER-2/neu protein overexpression in the primary tumor or metastasis; (2) advanced disease, but prior treatment yielding either no detectable cancer or minimal residual disease stable on hormonal or radiotherapy; (3) a competent immune system, as measured by re sponsiveness to a minimum of two of seven recall antigens by skin testing; (4) the clinical expecta tion to remain off any immunosuppressi ve therapy for 6 months; and (5) signed informed consent.
In addition to the patient population, the "dose escalation" of a peptide vaccine is all important issue. With standard chemotherapies, the dose of the drug is escalated based on the concept that increased dose delivered will result in a greater antitumor response. This concept is not true for vaccines. If the toxicity of a vaccine is related to the augmentation of the immune response, that augmentation may be elicited by repeated im munization rather than increasing the dose of the immunizing antigen. The "dose escalation" of a vaccine may not lay in the quantity of peptide delivered, but rather in the number of exposures to antigen (Le., the number of immunizations). In fact, high dose of antigen may have a detri mental effect on the ability to generate an im mune response.
The amount of peptide needed to stimulate an immune response has been well studied through many systems. Indeed, since 1985, there have been several phase I human studies of peptide vaccines or therapies: malaria vaccines, TCR pep tides for the treatment of multiple sclerosis, and peptide vaccines directed against tumor antigens such as ras."J44 Evaluating existing studies, dose of pep tides given as vaccines to humans has been "escalated" from 10 Ilg to over 3000 ~g. In gen eral, the immune responses generated in these studies was directly related to dose, the majority of responses being observed in doses ranging from 300 to 800 Ilg. In a study of immunization with TCR-derived peptides for the treatment of mul tiple sclerosis there was an indication that the peptide specific T cell immune response was sup pressed when the amount of peptide injected was greater than 1000 Ilg. 43 Our trial immunizes pa lients with 500 j.lg of each of the three peptides ill the ECD or ICD vaccine. As a "dose escalation," patients are vaccinated once a month for 6 months.
Laboratory assays to define HER-2!neu-spe cific immunity should be quantitative and statis tically based. The challenge is designing quanti tative assays using a limited amount of patient material. In the trial, HER-2/neu-specific T-cell proliferation is assessed by USing a modified lim iting dilution assay designed for detecting low frequency lymphocyte precursors,, 5 This method is based On Poisson distribution, a more appropri ate method for identifying randomly distributed responding cells of low number in replicate wells. A cutoff value of the mean and three standard deviations of the no-antigen wells is used to score a weIl as responding or nonresponding. AIl anti gens are set up in 24 well replicates. Responses can be quantified as the number of responding wells of 24 well replicate. Using this cutoff value. one has a 95% confidence interval that a well is positive due to the specific antigen added. This assay system allows for quantification of HER-2! neu-specific T helper responses after each se quential immunization and use a limited number of cells. Similar quantitative statistically based assays have been developed for the assessment of HER-2/ncu-specific CTL and antibody responses.
To date, eight patients have been immunized with the ECD or ICD vaccine. Initial results have been encouraging, with both HER-2!neu peptide and protein T-cell responses generated." Immu nization to a peptide derived from a tumor antigen protein is no guarantee that protein-specific T cell responses will be elicited. Thus far two of eight patients generated responses to peptides and had no response to protein. However, six of eight patients immunized to peptides developed pep tide-specific and protein-specific responses. The disparatel:U,A type of an outbred human popula tion might demand that the peptides be selected for particular patients. However, both class I and class II HLA typing have been performed on all patients enrolled in the study and to date there is no predominant haplotype that predicts response. The choice of patient population was important. Over 50% of the stage IV patients potentially eligible for the study were anergic by skin lesting and not enrolled. This inclnded patients who were in a complete rentission at the time of immuno logic assessment. No toxicities have been noted in the patients immunized, despite the generation of HER-2/neu-specific immunity, and the vaccine schedule has been very well tolerated.
Enrollment and vaccination continue. More patients are needed to determine whether these encouraging early results can be translated to a larger patient population. Finally, a randomized trial of patients in remission wifh minimal re sidual disease is needed to determine whether elicitation of an immune response to HER-2/neu can be translated into any therapeutic benefit. Regardless of outcome, the trial thus far has es tablished that peptide-based vaccines injected Ld. with GM-CSF as an adjuvant can induce a sub stantial immune response in huma"s to "self' tumor antigens.
